Current data on rapid and long-acting insulin analogues in the paediatric age group is limited. While several studies indicate a benefit in reducing hypoglycaemia, particularly at night, with rapid or long-acting insulin analogue treatment, the effect on long-term glycaemic control remains controversial. The continuous glucose monitoring system offers a new option for tailoring treatment with insulin analogues to achieve optimal glycaemia. In 29 adolescents with diabetes this approach confirmed the non-inferiority of postprandial rapid-acting analogue administration compared to preprandial regular insulin, but revealed significant mealtime differences, with increased analogue requirement at breakfast and dinner. Although rapid- and long-acting insulin analogues may offer potential benefits for problems frequently encountered in paediatric diabetology, their value for the individual child still has to be tested in long-term observations in daily clinical practice.

Keywords:
Aspart, Lispro, Glargin, Detemir, Continuous glucose monitoring, Children, Type 1 diabetes mellitus
1.
Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151–1167.
2.
Brunner GA, Sendhofer G, Wutte A, Ellmerer M, Sogaard B, Siebenhofer A, Hirschberger S, Krejs GJ, Pieber TR: Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diab 2000;108:100–105.
3.
Mortensen H, Lindholm A, Olsen B, Hyelleberg B: Rapid appearance and onset of action of insulin aspart in paediatric subjects with Type 1 diabetes. Eur J Pediatr 2000;159:483–488.
4.
Hedman CA, Lindstrom T, Arnqvist HJ: Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diab Care 2001;24:1120–1121.
5.
Raskin P, Guthrie R, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analogue, as the mealtime insulin in the management of patients with Type 1 diabetes. Diab Care 2000;23:583–588.
6.
Home P, Lindholm A, Riis A: Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomised controlled trial. Diab Med 2000;17:762–770.
7.
Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diab Care 1999;22:468–477.
8.
Gale EAM for the UK Trial Group: A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diab Med 2000;17:209–214.
9.
Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB: Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diab Care 1999;22:795–800.
10.
Fairchild JM, Ambler GR, Genoud-Lawton CH, Westman EA, Chan A, Howard NJ, Crock PA, Nunn EA, Silink M: Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin. Pediatr Diab 2000;1:135–141.
11.
Rave K, Heinemann L, Puhl L, Gudat U, Woodworth JR, Weyer C, Heise T: Premixed formulations of insulin lispro. Diab Care 1999;22:865–866.
12.
Weyer C, Heise T, Heinemann L: Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analogue in stable mixture. Diab Care 1997;20:1612–1614.
13.
Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, Atchison JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprrio E, Kocova M, Martul P, Matsuura M, Schoenle EJ, Søvik O, Swift PGF, Tsou RM, Vanelli M, Aman J, for The Hvidøvre Study Group on Childhood Diabetes: Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Diab Med 1998;15:752–759.
14.
Schoenle E on the behalf of the HOE 901/3003 Study Group: Insulin glargin lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia. Diabetologia 1999;42 (suppl 1):A235 (abstract).
15.
Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB: Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diab Care 2000;23:557–559.
16.
Pieber TR, Eugene-Jolchine I, Derobert E: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diab Care 2000;23:157–162.
17.
Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diab Care 2001;24:296–301.
18.
Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP, the study group for the development of pump therapy in diabetes: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diab Care 2000;23:1232–1235.
19.
Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diab Care 1999;22:1767–1768.
20.
Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP: Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001;107:351–356.
21.
Bode B, Strange P: Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with Type 1 diabetes. Diab Care 2001;24:69–72.
22.
Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diab Care 1999;22:784–788.
23.
Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440–443.
24.
Johansson UB, Adamson UC, Lins PE, Wredling RA: Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. Diab Metab 2000;26:192–196.
25.
Kaufman F, Halvorson M, Kim C, Pitucheewanont P: Use of insulin pump therapy at nighttime only for children 7–10 years of age with Type 1 diabetes. Diab Care 2000;23:571–573.
26.
Deiss D, Kordonouri O, Meyer K, Danne T: Long hypoglycaemic periods detected by subcutaneous continuous glucose monitoring in toddlers and pre-school children with diabetes mellitus. Diab Med 2001;18:337–338.
27.
Hopfenmüller W, Deiss D, Augustin D, Kordonouri O: Biometrical standards for ‘continuous glucose monitoring system’ (CGMS). J Ped Endocrinol Metab 2001(suppl 3)14:1053.
28.
Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR: Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diab Med 2000;17:371–375.
29.
Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA: Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diab Care. 1998;21:1777–1778.
30.
Rami B, Schober E: Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr 1997;156:838–840.
31.
Mohn A, Mohn A, Matyka K, HarrisDA, Ross KM, Edge JA, Dunger DB : Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diab Care 1999;22:27–32.
32.
Kong N, Ryder REJ: What is the role of between meal snacks with intensive basal bolus regimens using preprandial lispro? Diab Med 1999;16:325–331.
33.
Kong N, Kitchen MM, Ryder REJ: The use of insulin lispro for high sugar content snacks between meals in intensive insulin regimens. Diab Med 2000;17:331–332.
34.
Rutledge K, Chase H, Klingensmith G, Walravens PA, Slover RH, Garg SK: Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997;100:968–972.
35.
Deiss D, Aaman J, Schober E, Jacobsen JL, Friberg HH, Danne T for the ANA 1200 Study Group: Preprandial vs. postprandial insulin aspart treatment in type 1 diabetic children and adolescents. J Pediatr Endocr Metab 2001;14:1044 (abstract).
36.
Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, Kitson H, Perlman K, Spencer M: Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001;108:1175–1179.
37.
Travaglini MT, Garg SK, Chase HP: Use of insulin lispro in the outpatient management of ketonuria. Arch Pediatr Adolesc Med 1998;152:672–675.
38.
Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA: Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995;38:106–111.
39.
Ahmed AB, Home PD: Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diab Care 1998;21:1707–1713.
40.
Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM. Diab Care 1997;20:1287–1289.
41.
Kurtzhals P, Schaffer L, Sorensen A, Schäffer L, Sørensen A Kristensen C, Jonassen I, Schmid C, Trub T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 2000;49:999–1005.
42.
Bolli GB, Owens DR: Insulin glargin. Lancet 2000;356:443–445.
43.
Pieber TR, Brunner GA, Siebenhofer A: Insulin analogues. Diab Ann 1999;2:255–268.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.